Advertisement
GSK vs NVS
Which Stock Would AI Choose? GSK plc (GSK) vs. Novartis AG (NVS) Stock Comparison
Key Takeaways
- GSK has shown stronger year-to-date performance at approximately 12% compared to NVS's 8%, alongside superior one-year returns of over 50% versus 36%.
- GSK trades at a lower trailing P/E ratio (price-to-earnings ratio) of 14.5 versus NVS's 20.3, suggesting better relative valuation.
- Both companies benefit from recent pipeline advancements, with GSK focusing on respiratory and oncology, and NVS on gene therapies and malaria treatments.
- GSK exhibits higher return on equity (ROE) at 43% compared to NVS's 31%, indicating more efficient profit generation from shareholder equity.
- NVS maintains a larger market capitalization of around $281 billion versus GSK's $109 billion, reflecting greater scale.
Introduction
GSK plc (GSK) and Novartis AG (NVS) are prominent players in the pharmaceutical sector, specializing in vaccines, specialty medicines, and innovative therapies. This comparison is relevant for healthcare-focused investors and traders seeking exposure to stable dividend payers with growth potential amid evolving market dynamics, such as regulatory approvals and pipeline progress. By examining recent performance, financial metrics, and sector positioning, readers can assess relative strengths in a competitive industry where innovation drives long-term value. Both stocks offer insights into broader pharma trends, including respiratory treatments and gene therapies, aiding decisions on portfolio allocation or trading opportunities.
GSK Overview and Recent Performance
GSK plc, a UK-based global biopharma company, focuses on vaccines, specialty medicines in HIV, oncology, and respiratory diseases. Its market capitalization stands at approximately $109 billion, with shares trading around $54 in recent market activity. The stock has demonstrated robust momentum, with year-to-date gains near 12% and one-year returns exceeding 50%, outperforming broader indices. Recent sentiment has been bolstered by pipeline advancements, including respiratory breakthroughs like depemokimab approvals and partnerships such as the 4DMedical lung imaging deal. Legal wins in licensing disputes and upcoming earnings have further supported stability, though shares remain sensitive to sector volatility and regulatory news. GSK's lower P/E ratio of 14.5 reflects attractive valuation amid these positive developments.
NVS Overview and Recent Performance
Novartis AG, headquartered in Switzerland, develops innovative medicines across cardiovascular, immunology, neuroscience, and gene therapies, with a market cap of about $281 billion and shares near $145 recently. Year-to-date performance is around 8%, with one-year gains of 36%, reflecting steady but less aggressive momentum compared to peers. Key influences include positive European Medicines Agency opinions for its SMA gene therapy Itvisma and WHO prequalification for Coartem Baby malaria treatment, enhancing access in underserved markets. Analyst targets average $153, signaling optimism, though recent pullbacks tie to broader healthcare sector pressures. Novartis's scale and diversified portfolio provide resilience, supported by a trailing P/E of 20.3.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of 25 top-performing AI trading bots from over 350 available, designed for copy trading across thousands of tickers. These bots employ diverse strategies, timeframes (like 5-minute to 60-minute charts), and themes such as semiconductors, finance, and commodities, with impressive stats including annualized returns up to 168%, win rates reaching 88%, and profit factors as high as 11.7. Maximum drawdowns vary, offering risk-managed options for different styles. While none currently focus on GSK or NVS, the platform’s real-time signals and performance tracking help traders adapt to market conditions. Explore these bots to enhance your strategy with data-driven automation.
Head-to-Head Comparison
In business models, GSK emphasizes vaccines and established specialty areas like HIV and respiratory, while NVS leans toward cutting-edge gene and cell therapies. Growth drivers differ: GSK benefits from higher ROE (43%) and recent momentum, contrasting NVS's larger revenue base ($57 billion ttm) and net income superiority. Recent momentum favors GSK with stronger YTD and one-year gains, though NVS shows lower debt-to-equity (76% vs. 111%). Risk factors include patent cliffs and regulatory hurdles for both, with GSK facing higher leverage but lower P/S ratio (2.5 vs. 5.0). Market sentiment is positive across the board, driven by pipeline catalysts, positioning GSK for value plays and NVS for growth stability in the pharma sector.
Tickeron AI Verdict
Tickeron’s AI models currently lean toward GSK over NVS, based on superior recent trend consistency, higher YTD and one-year returns, elevated ROE, and more compelling valuation metrics like lower P/E and PEG ratios. While NVS offers scale and innovation catalysts, GSK's relative momentum and efficiency suggest higher probability of near-term outperformance in current conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Buy and NVS is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).
- GSK’s FA Score: 2 green, 3 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 7 bullish TA indicator(s).
- GSK’s TA Score: 6 bullish, 3 bearish.
- NVS’s TA Score: 7 bullish, 2 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а +3.61% price change this week, while NVS (@Pharmaceuticals: Major) price change was +5.66% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +5.39%. For the same industry, the average monthly price growth was +13.43%, and the average quarterly price growth was +8.67%.
Reported Earning Dates
GSK is expected to report earnings on Jul 28, 2026.
NVS is expected to report earnings on Jul 21, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+5.39% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GSK | NVS | GSK / NVS | |
| Capitalization | 105B | 296B | 35% |
| EBITDA | 10.1B | 22.4B | 45% |
| Gain YTD | 8.902 | 16.129 | 55% |
| P/E Ratio | 13.50 | 21.34 | 63% |
| Revenue | 32.8B | 56.6B | 58% |
| Total Cash | 3.44B | 6.98B | 49% |
| Total Debt | 19.1B | 47B | 41% |
GSK | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 16 Undervalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 38 | 6 | |
SMR RATING 1..100 | 27 | 27 | |
PRICE GROWTH RATING 1..100 | 49 | 47 | |
P/E GROWTH RATING 1..100 | 78 | 36 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (6) in the Pharmaceuticals Major industry is in the same range as GSK (16). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
NVS's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is in the same range as GSK (38). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
NVS's SMR Rating (27) in the Pharmaceuticals Major industry is in the same range as GSK (27). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
NVS's Price Growth Rating (47) in the Pharmaceuticals Major industry is in the same range as GSK (49). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
NVS's P/E Growth Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (78). This means that NVS’s stock grew somewhat faster than GSK’s over the last 12 months.
| GSK | NVS | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 66% | 1 day ago 41% |
| Momentum ODDS (%) | 1 day ago 43% | 1 day ago 46% |
| MACD ODDS (%) | 6 days ago 51% | 1 day ago 60% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 52% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 48% |
| Advances ODDS (%) | 1 day ago 62% | 1 day ago 51% |
| Declines ODDS (%) | 10 days ago 54% | 10 days ago 45% |
| BollingerBands ODDS (%) | 1 day ago 66% | 1 day ago 51% |
| Aroon ODDS (%) | 1 day ago 45% | 1 day ago 48% |
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To GSK | 1D Price Change % | ||
|---|---|---|---|---|
| GSK | 100% | +1.18% | ||
| NVS - GSK | 64% Loosely correlated | +0.19% | ||
| BMY - GSK | 54% Loosely correlated | +3.85% | ||
| AMGN - GSK | 53% Loosely correlated | +1.56% | ||
| MRK - GSK | 52% Loosely correlated | +2.56% | ||
| BIIB - GSK | 46% Loosely correlated | +6.97% | ||
More | ||||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.